Italy as the Bottleneck: What the Covenant Breach Really Means at PowerGen Solar I
The main article already showed that financing, not asset quality alone, is the bottleneck at PowerGen Solar I. This follow-up shows why Italy is the clearest proof: almost all of the drawn exposure was hedged, yet debt-service coverage still failed twice, EUR 6 million was drawn from the reserve, and equity cures were needed to keep the structure in line.
Where The Main Article Stopped, And What This Follow-Up Is Isolating
The main article already made the broader point: PowerGen Solar I's assets look better than the financing layer sitting on top of them. This follow-up isolates the Italian piece, because that is where the phrase "financing sets the pace" becomes concrete: a dedicated non-recourse project-finance layer with reserves, hedges, coverage tests, and equity cures.
The core insight is simple, but not trivial. The Italian issue is not that the company forgot to hedge Euribor. It hedged almost all of the drawn exposure. And yet the historical ADSCR fell below the threshold on June 30, 2025 and again on December 31, 2025, EUR 6 million was drawn from the debt-service reserve, EUR 2 million of equity was injected in December 2025 to obtain a waiver for the June test, and at publication the company said it had sources for another EUR 5.6 million cure for the December breach.
That is the point. Once the covenant breaks twice even after near-full hedging, the central risk is no longer "open rates." It is cash coverage at the asset layer that has become too thin relative to the debt stack.
The Event Map: Not A Technical Miss, But A Sequence Of Reserve Use And Cure Capital
Under the Italian financing agreement signed in December 2022, the total framework was about EUR 139 million. The loan bears Euribor plus a 2.3% margin, requires interest hedging of at least 75% of debt, and is tested twice a year. The breach threshold is ADSCR of 1.05, and that is exactly where the failure showed up.
| Point in time | What happened | Why it matters |
|---|---|---|
| December 2022 | Italy financing was signed at about EUR 139 million | This is a relatively self-contained project-finance layer with its own coverage tests and reserves |
| June 2025 | EUR 6 million was drawn from the DSRF, the debt service reserve facility, to meet scheduled repayment on June 30, 2025 | Once the reserve is being used to meet the amortization schedule, the buffer is already being consumed |
| June 30, 2025 | Historical ADSCR fell below 1.05 | This is not a cosmetic accounting wobble. It is a failure to meet the minimum coverage floor |
| December 18, 2025 | About EUR 2 million of equity was injected to obtain a waiver for the June breach | The repair came from sponsor capital, not only from internal asset cash generation |
| December 31, 2025 | The year-end test also failed the same floor | The problem repeated across two consecutive test dates |
| At publication | The company said it had sources for another roughly EUR 5.6 million equity injection | As of the report date, the issue had not yet been cured through organic recovery in coverage |
There is another detail that sharpens the read. By publication, about EUR 71 million had been drawn under the Italian financing, and about EUR 34.5 million of that had already been used for equity release. In other words, this debt layer was not just sitting underneath the assets. It had already helped pull capital out, and now capital had to go back in to preserve compliance. That does not automatically make the deal wrong. It does mean the margin for error is narrower than the label "Italian operating assets" might suggest.
Why Almost 95% Hedging Did Not Solve The Problem
The company was required to hedge at least 75% of debt, and by publication it had hedging agreements for EUR 66.8 million against about EUR 71 million drawn. The fixed base rate under those hedges ranged from 2.8% to 3.1%. This is not a picture of reckless Euribor exposure.
In plain terms, the hedges did what they were supposed to do: they cut a large part of the interest-rate risk. What they could not do, and were never meant to do, was create cash coverage if the asset cash flows left after operating costs and debt service had become too thin.
The financial-instruments note points in the same direction. At the end of 2025 the group had euro-denominated financial assets of NIS 114.2 million against euro-denominated financial liabilities of NIS 225.5 million, leaving a net euro liability position of NIS 111.4 million. The sensitivity test says a 5% move in the euro would change equity or total comprehensive income by about NIS 5.6 million. That is a real exposure, but it is not the main story here.
The main story is that the Italian assets remain economically variable even after the hedge book is in place. Revenue there is built on two different legs: a fixed subsidy that is not indexed to inflation, and electricity-sale revenue that is tied to market prices. At the same time, the company carries lease and operating costs, and the financing agreement tests historical ADSCR. So interest hedging can reduce one layer of pressure, but it cannot turn this portfolio into a fixed coupon. If the cash left for debt service weakens, the covenant can still break even with near-full hedging.
Put more sharply: the hedge is designed to stop rates from burning the business. It cannot manufacture coverage where the coverage itself has become too thin.
What Series C Does, And What It Does Not
February 2026 does add relief at the group level. The company expanded Series C by NIS 82 million par value for immediate gross proceeds of about NIS 81 million. The stated use of proceeds is clear: repay project loans at the companies holding the small-systems portfolio, improve cash flow, and save interest.
That matters, but it matters just as much not to claim more than the filing says. There is no disclosure that these proceeds were earmarked to cure the Italian financing. On the contrary, the Italian remedy is described as an equity injection under the terms of the Italian agreement itself. So the Series C expansion is supportive financing context, not a direct solution to the Italian bottleneck.
That is the difference between group-level pressure and project-level pressure. At the group level, Series C can improve the debt mix, lower interest cost in the small-systems layer, and maybe release some room. In Italy, the test is different: can the assets themselves get back to ADSCR above 1.05 without further DSRF use and without going back to sponsor capital again.
What This Means For The Value That Is Actually Accessible
The main article argued that value at PowerGen Solar I is still trapped inside the financing layer. Italy shows exactly what that looks like once the idea is translated into numbers.
This is not necessarily an immediate insolvency story. It is an accessible-value story. There are assets, there is cash generation, there is hedging, and there is still access to the bond market. But before that value becomes free, it has to move through reserves, coverage tests, amortization schedules, and cure injections. As long as that layer still leans on reserve draws and supporting equity, Italy remains the bottleneck rather than the proof point.
What has to happen now for the read to improve? Not more talk about hedging, because the hedge is already there. The next test has to pass without a waiver, without DSRF use, and without new cure equity. Only then can the Italian layer be read again as financing that serves the assets, rather than financing the assets are still trying to catch up with.
Conclusion
The Italian covenant breach matters precisely because it shows what a reader should not miss. It is easy to look at roughly 95% hedging, a EUR 139 million financing framework, and a post-balance-sheet Series C expansion, and conclude that the risk is mainly technical. That is too soft a reading.
The harder, and more accurate, read is that the Italian layer has already shown that the weak link is not the mere existence of debt or the lack of hedging. The weak link is the residual margin left after debt. When that margin is not enough, the reserve gets used, then the waiver arrives, and then capital follows. That is exactly the sequence in which project finance stops being just an efficient lever and becomes the bottleneck of the whole story.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.